# Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC

> **NCT03432949** · PHASE4 · UNKNOWN · sponsor: **University Health Network, Toronto** · enrollment: 24 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Dexamethasone plus Radium-223

## Key facts

- **NCT ID:** NCT03432949
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-23
- **Primary completion:** 2023-09-30
- **Final completion:** 2024-07-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03432949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03432949, "Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03432949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*